Please provide your email address to receive an email when new articles are posted on . The addition of azacitidine to venetoclax significantly improved response rates and OS among certain patients ...

Like many cancers, acute myeloid leukemia (AML) has been a major beneficiary from the introduction of targeted therapies into the oncology treatment landscape. In fact, 1 of the earliest uses of ...

Please provide your email address to receive an email when new articles are posted on . The analysis included treatment-naive patients with AML who had been deemed unfit for intensive chemotherapy ...

An observational study recently published in Cancer highlights a notable correlation between glucose-6-phosphate dehydrogenase (G6PD) deficiency and improved clinical outcomes among patients with ...

MADRID, Spain and CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop ...

For older patients with acute myeloid leukemia (AML) who are not eligible for chemotherapy, adding venetoclax (Venclexta, Venclyxto) to azacitidine significantly improved overall survival, complete ...

Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses The patients included in this ...

in AML in its ongoing Phase 1/2a EVICTION study The FDA designed Fast Track status to facilitate the development and expedite the review of therapeutic candidates that have the potential to treat ...

Adding the menin inhibitor revumenib (Revuforj) to azacitidine and venetoclax (Venclexta) seemed to benefit older adults with newly diagnosed NPM1-mutated or KMT2A-rearranged acute myeloid leukemia ...

Please note - this trial is no longer recruiting patients. We hope to add results when they are available. This trial is comparing venetoclax and azacitidine with azacitidine for acute myeloid ...

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced new safety and efficacy ...

Evaluation of the Clinical Utility of the Bone Metastases Ensemble Trees for Survival Decision Support Platform (BMETS-DSP): A Case-Based Pilot Assessment Data on 221 newly diagnosed patients with AML ...